At 20.0% CAGR, North America Human Microbiome Market is Projected to be Worth US$ 2,811.82 Million by 2031, says Business Market Insights

According to Business Market Insights research, the North America human microbiome market was valued at US$ 654.89 million in 2023 and is expected to reach US$ 2,811.82 million by 2031, registering a CAGR of 20.0% from 2023 to 2031. Significant investments by key market players and government initiatives are among the critical factors attributed to drive the North America human microbiome market growth.

The human microbiome industry's growth, innovation, and market dynamics are greatly influenced by the investments made by major players in the market. Major players are engaged in making significant investments in research and development to create novel probiotics, diagnostics, and treatments based on the microbiome. These expenditures stimulate innovation, identifying new strains, modes of action, and medicinal uses. Clinical trials receive a large amount of funding, which is essential for demonstrating the effectiveness and safety of products based on the microbiome. A pioneer in microbiome mapping technology, Kanvas Biosciences, announced a US$ 12 million Pre-Series A funding round in June 2023. The company's proprietary platform technology, which has the potential to transform drug development into illnesses linked to the microbiome, will be further developed with the help of the investment. These partnerships make sharing resources, know-how, and technological advancements easier, speeding up product development. For instance, a new collaboration was announced between the world's largest food and beverage company, Nestlé, and a top-tier SFI research center, APC Microbiome Ireland, in July 2023. The collaboration centers on different aspects of the human microbiome and helps develop new products to enhance human health and wellness. As many as 120 companies are reportedly investing in microbiome analysis, and numerous startups are entering this field. Flagship Pioneering, Seventure Partners, and BioGaia are the most active investors. Thus, increase in investments by key players is likely to drive the growth of market.

On the contrary, the challenges during production of microbiomes hamper the growth of North America human microbiome market.

Based on type, the North America human microbiome market is bifurcated into product and software and services. The product segment held 60.0% market share in 2023, amassing US$ 392.74 million. It is projected to garner US$ 1,553.51 million by 2031 to register 18.8% CAGR during 2023–2031. The product segment is further sub segmented into probiotics and prebiotics.

By application, the North America human microbiome market is segmented into therapeutics, diagnostics, and research. The therapeutics segment held 57.8% share of North America human microbiome market in 2023, amassing US$ 378.29 million. It is anticipated to garner US$ 1,665.03 million by 2031 to expand at 20.4% CAGR during 2023–2031.

By disease type, the North America human microbiome market is segmented into obesity, diabetes, autoimmune disorder, cancer, GIT, and others. The GIT segment held 35.0% market share in 2023, amassing US$ 229.11 million. It is projected to garner US$ 1,048.25 million by 2031 to register 20.9% CAGR during 2023–2031.

By country, the North America human microbiome market is segmented into the US, Canada, and Mexico. Our regional analysis states that the US captured 94.1% share of North America human microbiome market in 2023. It was assessed at US$ 616.38 million in 2023 and is likely to hit US$ 2,672.50 million by 2031, registering a CAGR of 20.1% during 2023–2031.

Key players operating in the human microbiome market are MaaT Pharma; Ferring Holdings SA; AOBiome Therapeutics Inc; Finch Therapeutics Group Inc; Seres Therapeutics Inc; Merck & Co Inc; Rebiotix, Inc.; Yakult Honsha Co., Ltd.; IFF Nutrition & Biosciences; and Synthetic Biologics, Inc. among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com